New York State Common Retirement Fund Sells 7,956 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Common Retirement Fund trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 64,272 shares of the biopharmaceutical company's stock after selling 7,956 shares during the quarter. New York State Common Retirement Fund's holdings in Alnylam Pharmaceuticals were worth $17,355,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of ALNY. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Commonwealth Equity Services LLC boosted its position in shares of Alnylam Pharmaceuticals by 23.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,537 shares of the biopharmaceutical company's stock valued at $1,538,000 after acquiring an additional 1,234 shares during the last quarter. Natixis Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 4.5% in the 4th quarter. Natixis Advisors LLC now owns 10,453 shares of the biopharmaceutical company's stock valued at $2,460,000 after buying an additional 451 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in Alnylam Pharmaceuticals by 74.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,062 shares of the biopharmaceutical company's stock valued at $485,000 after buying an additional 880 shares during the period. Finally, Intech Investment Management LLC raised its holdings in Alnylam Pharmaceuticals by 6.0% in the 4th quarter. Intech Investment Management LLC now owns 7,573 shares of the biopharmaceutical company's stock valued at $1,782,000 after buying an additional 428 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $4.16 on Friday, hitting $320.53. The company's stock had a trading volume of 581,322 shares, compared to its average volume of 852,386. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $333.70. The company has a market capitalization of $41.79 billion, a price-to-earnings ratio of -153.36 and a beta of 0.23. The stock's 50-day moving average is $306.46 and its two-hundred day moving average is $271.78. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter last year, the company earned ($0.16) EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALNY. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a research note on Wednesday. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a report on Monday, June 30th. HC Wainwright reaffirmed a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target for the company. Finally, Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have assigned a buy rating to the company's stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $346.13.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.